Fabrication and Experimental Study of Micro/Sub-Micro Porous Copper Coating for Anti-Icing Application.

Micro and sub-micro-spherical copper powder slurries were elaborately prepared to fabricate different types of porous coating surfaces. These surfaces were further treated with low surface energy modification to obtain the superhydrophobic and slippery capacity. The surface wettability and chemical component were measured.

Condensation Flow Heat Transfer Characteristics of Stainless Steel and Copper Enhanced Tubes.

In order to study the heat transfer of R410A in extreme environments, the properties of several stainless steel and copper-enhanced tubes were evaluated using R410A as the working fluid, and the results were compared with those of smooth tubes. Tubes evaluated include: smooth, herringbone (EHT-HB) and helix (EHT-HX) microgroove, herringbone/dimple (EHT-HB/D); herringbone/hydrophobic (EHT-HB/HY); and composite enhancement 1EHT (three-dimensional). Experimental conditions include a saturation temperature of 318.

Apoptosis Induction in Primary Human Colorectal Cancer Cell Lines and Retarded Tumor Growth in SCID Mice by Sulforaphane.

We have investigated the anticancer effects of the dietary isothiocyanate sulforaphane (SFN) on colorectal cancer (CRC), using primary cancer cells lines isolated from five Taiwanese colorectal cancer patients as the model for colorectal cancer. SFN-treated cells accumulated in metaphase (SFN 6.25 μM) and subG1 (SFN 12.

Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.

Unlabelled: To evaluate the efficacy and toxicity of gemcitabine plus cisplatin (GC) chemotherapy in patients with recurrent and metastatic nasopharyngeal carcinoma (NPC), 75 patients of Chinese ethnicity with recurrent and metastatic NPC received a combination of gemcitabine 1000 mg/m2 on days 1 and 8, and cisplatin 25mg/m2 on days 1, 2 and 3 of a 21-day cycle. All patients were ineligible for re-irradiation or surgery. Of the 75 patients, 4 achieved a complete response, and 28 patients achieved a partial response, for an overall response rate of 42.

[Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].

Objective: To evaluate the efficacy and toxicity of combination chemotherapy using gemcitabine plus cisplatin for recurrent and/or metastastic head and neck cancer patients.

Methods: Fifty-two patients with recurrent or metastatic head and neck cancer were treated by gemcitabine 1000 mg/m(2) on D1, 8 and cisplatin 25 mg/m(2) on D1 approximately 3 every 21 days as one cycle.

Results: Of 52 assessable patients, 3 (5.